04:51 , Nov 3, 2017 |  BC Week In Review  |  Company News

Novartis offers $3.9B to acquire Advanced Accelerator

Novartis AG (NYSE:NVS; SIX:NOVN) offered to acquire Advanced Accelerator Applications S.A. (NASDAQ:AAAP) for $82 per ADS in a deal the companies say values Advanced Accelerator at $3.9 billion. The price is a 12% premium on...
02:19 , Feb 24, 2017 |  BC Week In Review  |  Clinical News

DB1038: Ph I started

Dauntless began a crossover, U.S. Phase I trial to compare intranasal DP1038 vs. subcutaneous Sandostatin octreotide acetate in about 32 healthy volunteers. Dauntless is developing DP1038 under section 505(b)(2) of the Food, Drug and Cosmetic...
07:00 , Mar 28, 2016 |  BC Week In Review  |  Clinical News

Mycapssa octreotide: Phase III started

Chiasma began the open-label, international Phase III MPOWERED trial to compare 40, 60 and 80 mg/day oral Mycapssa vs. monthly injectable somatostatin analogs for 9 months in about 150 patients who received somatostatin analog injections...
07:00 , Mar 24, 2016 |  BC Innovations  |  Product R&D

Liver-bound

Ionis Pharmaceuticals Inc. is retooling its antisense technology with a sugar-based conjugate that boosts uptake into liver cells. By tapping the power of GalNAc sugars to latch onto hepatocyte receptors, the company believes it can...
07:00 , May 25, 2015 |  BC Week In Review  |  Company News

Antisense Therapeutics, Cortendo deal

Antisense granted Cortendo exclusive rights to develop and commercialize ATL1103 for endocrinology indications. Antisense will receive $5 million up front and is eligible for up to $105 million in development and commercialization milestones, plus royalties....
07:00 , Mar 9, 2015 |  BC Week In Review  |  Clinical News

Octreotide acetate: Additional Phase III data

Chiasma reported additional data from an open-label, international Phase III trial in 151 evaluable adults with acromegaly showing that baseline control on injectable somatostatin analogs could predict a subsequent response to oral octreotide, defined as...
08:00 , Feb 16, 2015 |  BC Week In Review  |  Clinical News

Octreolin octreotide acetate: Phase III data

An open-label, international Phase III trial in 155 adults with acromegaly showed that 65% of patients who received oral octreotide achieved the primary endpoint of maintaining IGF-1 levels of <1.3 times the upper limit of...
07:00 , Sep 8, 2014 |  BC Week In Review  |  Clinical News

ATL1103: Additional Phase II data

An open-label, European and Australian Phase II trial in 26 acromegalic patients showed that 200 mg ATL1103 given 3 times in week 1 followed by twice-weekly 200 mg ATL1103 for 12 weeks met the primary...
07:00 , Sep 8, 2014 |  BioCentury  |  Finance

Highlights of weekly biotech stock moves

Regulatory milestones Acadia Pharmaceuticals Inc. (NASDAQ:ACAD) gained $2.63 (11%) to $26.61 on Tuesday after FDA granted breakthrough therapy designation to Nuplazid pimavanserin to treat Parkinson's disease psychosis. The compound has completed a Phase III trial...
00:49 , Sep 4, 2014 |  BC Extra  |  Clinical News

Antisense reports acromegaly data

Antisense Therapeutics Ltd. (ASX:ANP) said 200 mg of ATL1103 twice-weekly met the primary endpoint in a 26-patient, open-label Phase II trial to treat acromegaly. That dosage reduced serum insulin-like growth factor-1 ( IGF-1 ) levels...